Clinical trials: Methicillin-Sensitive Staphylococcus Aureus Infection
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
Staphylococcus aureus (S.aureus) is a bacterium that causes many painful skin and soft tissue conditions, such as scalded-skin syndrome, boils, or impetigo.
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
- Trial name
- MRSA (NCT00822276)
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage cocktail to treat and prevent the recurrence of a methicillin-susceptible Staphylococcus aureus prosthetic joint infection…
- Trial name
- PHAGE-2024-01 (NCT06456424)
- Testing
- Phage therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Nasal Carriers MRSA
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)
This is a pilot study conducted to evaluate the safety, local tolerability and efficacy of LTX-109(Lytixar™), a lytic peptide designed to kill bacterias quickly and efficient.
- Trial name
- NCT01158235
- Testing
- LTX-109
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lytix Biopharma AS
the Aim of This Study is to Describe Genomic Epidemiology of MSSA in Neonatal ICU
Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology
Newborns hospitalized in Neonatology are particularly vulnerable to infections, in particular healthcare associated infection (HAI).
- Trial name
- NEOSAUR (NCT06267352)
- Volunteers
- 120 people
- Sponsor
- University Hospital, Caen
Bacterial Resistance, Methicillin-Sensitive Staphylococcus Aureus Infection
Antistaphylococcal Betalactam and Emergence of Resistance
Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with…
- Trial name
- CePasR (NCT05939479)
- Where
- France
- Volunteers
- 644 people
- Sponsor
- Central Hospital, Nancy, France